Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	$ 933
Provision	[2]	56	$ 10
Utilization and other	[3]	(275)
Balance, March 29, 2020	[4]	714
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	887
Provision		25
Utilization and other	[3]	(243)
Balance, March 29, 2020	[4]	669
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	0
Provision		31
Utilization and other	[3]	(31)
Balance, March 29, 2020	[4]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	46
Provision		0
Utilization and other	[3]	(1)
Balance, March 29, 2020	[4]	$ 45

[1] Included in Other current liabilities ($714 million) and Other noncurrent liabilities ($219 million).

[2] In the first quarter of 2020, restructuring charges mainly represent asset write-downs and employee termination costs associated with cost reduction initiatives. In the first quarter of 2019, restructuring charges were primarily associated with cost reduction initiatives and mainly represent asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. The restructuring activities for the first quarter of 2020 are associated with the following: • Biopharma ($2 million charge); Upjohn ($13 million charge); and Other ($41 million charge). The restructuring activities for the first quarter of 2019 are associated with the following: • Biopharma ($13 million charge); Upjohn ($13 million credit); and Other ($10 million charge).

[3] Includes adjustments for foreign currency translation.

[4] Included in Other current liabilities ($532 million) and Other noncurrent liabilities ($182 million).